Kidney Sodium Functional Imaging

NCT05014178Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sChristopher McIntyreChristopher McIntyre

Actively Recruiting

View on ClinicalTrials.gov ↗

About This Study

This pilot exploratory study evaluates the use of 23Na MRI to quantify the renal corticomedullary sodium gradient in approximately 200 patients with CKD, nephrolithiasis, or ADPKD. Investigators utilize sodium-specific functional imaging to non-invasively measure medullary sodium concentration, a key determinant of urinary concentrating capacity. Clinical assessments include standardized blood pressure monitoring, serum labs, and spot UPCR/UACR, with 24-hour urine collections required for the nephrolithiasis cohort. The study aims to determine if alterations in the sodium gradient correlate with disease progression and to validate 23Na MRI as a functional biomarker for renal medullary health.

Who Can Participate?

✓ Inclusion Criteria

  • •Age ≥ 18 years
  • •For healthy controls: lack of kidney disease, heart failure, liver cirrhosis and peripheral edema
  • •For CKD stage 1-5: Estimated GFR < 90 mL/min/1.73m²
  • •For patients on maintenance hemodialysis or peritoneal dialysis: more than 3 months duration of therapy

✗ Exclusion Criteria

  • •Pregnant, breastfeeding or intending pregnancy
  • •Contraindication to MRI
  • •Inability to tolerate MRI due to patient size and/or known history of claustrophobia.
  • •Mechanically implanted, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, tattoos, shunt, surgical staples (including clips or metallic sutures and/or ear implants.)